Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M) ($M)
Form 10-Q / 10-K Stock-Based Compensation Note (XBRL)
Latest, Q2 2026
165
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
157 in Q2 2025
History
30 quarters
Since Q1 2015
Sources
17
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 165 | +5.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 75 | -11.8% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 125 | -6.7% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 127 | -6.6% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 157 | 0.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 85 | -17.5% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 134 | -16.8% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 136 | +30.8% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 157 | +31.9% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 103 | +119.1% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 161 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 104 | – | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 119 | – | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 47 | – | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 87 | +2.4% | Form 10-K (filed 2021-02-09) ↗ |
| Q3 2018 | Sep 30, 2018 | 77 | -12.5% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 93 | -3.1% | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2018 | Mar 31, 2018 | 54 | -10.0% | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2017 | Dec 31, 2017 | 85 | -4.5% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 88 | +6.0% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 96 | +10.3% | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 60 | +15.4% | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2016 | Dec 31, 2016 | 89 | +11.3% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2016 | Sep 30, 2016 | 83 | +1.2% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 87 | -3.3% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 52 | -25.7% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 80 | – | Form 10-K (filed 2018-02-13) ↗ |
| Q3 2015 | Sep 30, 2015 | 82 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 90 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 70 | – | 10-Q FY2015 (XBRL) ↗ |
Breakdown
What makes up stock-based compensation (sbc) — total pre-tax expense ($m)
- SBC Income Tax Benefit ($M)–
- SBC Expense, Net of Tax ($M)–
- SBC Expense by Award Type — Restricted Stock Units (RSUs) ($M)–
- SBC Expense by Award Type — Performance Units (PSUs) ($M)–
- SBC Expense by Award Type — Stock Options ($M)–
- Unrecognized SBC Compensation Cost — Total ($M)–
- Shares Available for Future Grant Under Equity Incentive Plan (M shares)–
- Stock Options — Shares Outstanding at Period End (M shares)–
- Restricted Stock Units (RSUs) — Nonvested Shares Outstanding (M shares)–
- Performance Units (PSUs) — Nonvested Units Outstanding (M shares)–
Cite this data
StockData. (2026). Amgen Stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/sbc_exp_tot
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.